SomaLogic, Inc. (SLGCW)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
SomaLogic, Inc. (SLGCW) with AI Score 55/100 (Hold). SomaLogic, Inc. is a protein biomarker discovery and clinical diagnostics company. They develop and offer SOMAmer-based protein analysis services for drug discovery, clinical trials, and disease diagnostics. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026SomaLogic, Inc. (SLGCW) Healthcare & Pipeline Overview
SomaLogic, Inc. pioneers protein biomarker discovery and clinical diagnostics through its proprietary SOMAmer technology. The company offers SomaScan services for multiplex protein analysis, serving pharmaceutical, biotechnology, and academic research sectors. With a focus on advancing drug development and disease diagnostics, SomaLogic operates in the competitive healthcare information services industry.
Investment Thesis
SomaLogic, Inc. presents a compelling investment case centered on its proprietary SomaScan technology and its potential to transform protein biomarker discovery and clinical diagnostics. The company's ability to provide multiplex protein analysis offers significant value to pharmaceutical and biotechnology companies, driving revenue growth. Key value drivers include expanding the application of SomaScan in drug development and clinical trials, as well as increasing adoption in diagnostic applications. The company's gross margin of 55.6% indicates a strong pricing power. However, the company's negative profit margin of -111.8% and a beta of 1.64 suggest higher volatility and risk. The company's market capitalization is $0.40 billion as of March 16, 2026. Upcoming catalysts include potential partnerships with major pharmaceutical companies and expansion into new therapeutic areas. Potential risks include competition from alternative protein analysis technologies and regulatory hurdles in diagnostic applications.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.40 billion reflects the company's current valuation in the market.
- Gross Margin of 55.6% indicates the profitability of SomaLogic's core services.
- Profit Margin of -111.8% highlights the company's current challenges in achieving overall profitability.
- The company's focus on protein biomarker discovery and clinical diagnostics positions it in a high-growth area of healthcare.
- The development of SOMAmers technology provides a unique competitive advantage in protein analysis.
Competitors & Peers
Strengths
- Proprietary SOMAmer technology provides a competitive advantage.
- SomaScan platform enables multiplex protein analysis.
- Strong focus on protein biomarker discovery and clinical diagnostics.
- Established customer base in pharmaceutical and biotechnology companies.
Weaknesses
- Negative profit margin indicates challenges in achieving profitability.
- High beta suggests higher volatility compared to the market.
- Reliance on a single technology platform may limit diversification.
- Limited geographic presence compared to larger competitors.
Catalysts
- Upcoming: Potential partnerships with major pharmaceutical companies to integrate SomaScan into drug development programs.
- Upcoming: Expansion into new therapeutic areas such as oncology and immunology.
- Ongoing: Increased adoption of SomaScan in clinical diagnostics and laboratory-developed tests.
- Ongoing: Development of new SomaScan assays and applications to address unmet needs in research and clinical practice.
Risks
- Potential: Competition from alternative protein analysis technologies and diagnostic platforms.
- Potential: Regulatory hurdles in diagnostic applications and commercialization of new tests.
- Potential: Patent expiration risks for SOMAmer technology and potential for generic competition.
- Ongoing: Negative profit margin and challenges in achieving overall profitability.
- Ongoing: Dependence on key personnel and potential for loss of expertise.
Growth Opportunities
- Expansion into New Therapeutic Areas: SomaLogic has the opportunity to expand the application of its SomaScan platform into new therapeutic areas beyond its current focus on cardiovascular and metabolic diseases. This includes areas such as oncology, immunology, and neurodegenerative diseases. The market size for biomarker discovery in these areas is substantial, with significant unmet needs for improved diagnostics and drug development tools. The timeline for this expansion is ongoing, with potential for revenue growth within the next 2-3 years. SomaLogic's competitive advantage lies in its ability to provide comprehensive protein analysis across a wide range of therapeutic areas.
- Strategic Partnerships with Pharmaceutical Companies: SomaLogic can drive growth by forming strategic partnerships with major pharmaceutical companies. These partnerships can involve the use of SomaScan in drug development programs, clinical trials, and biomarker discovery initiatives. The market size for pharmaceutical partnerships is significant, with potential for long-term revenue streams and validation of SomaLogic's technology. The timeline for securing these partnerships is ongoing, with potential for announcements within the next 1-2 years. SomaLogic's competitive advantage lies in its ability to provide valuable insights into protein biomarkers, accelerating drug development and improving clinical trial outcomes.
- Increased Adoption in Clinical Diagnostics: SomaLogic has the opportunity to increase the adoption of its SomaScan platform in clinical diagnostics. This includes the development and commercialization of laboratory-developed tests (LDTs) and diagnostic assays for various diseases. The market size for clinical diagnostics is substantial, with a growing demand for personalized medicine and early disease detection. The timeline for this expansion is ongoing, with potential for revenue growth within the next 3-5 years. SomaLogic's competitive advantage lies in its ability to provide accurate and comprehensive protein analysis, enabling more precise and personalized diagnostic approaches.
- Geographic Expansion into International Markets: SomaLogic can drive growth by expanding its geographic presence into international markets, particularly in Europe and Asia. These markets offer significant opportunities for the adoption of SomaScan in research and clinical applications. The market size for protein biomarker discovery and clinical diagnostics in these regions is substantial, with a growing demand for advanced technologies. The timeline for this expansion is ongoing, with potential for revenue growth within the next 2-4 years. SomaLogic's competitive advantage lies in its ability to provide a differentiated and comprehensive protein analysis platform.
- Development of New SomaScan Assays and Applications: SomaLogic can drive growth by continuously developing new SomaScan assays and applications to address unmet needs in research and clinical practice. This includes the development of assays for specific disease biomarkers, as well as applications in areas such as drug response prediction and patient stratification. The market size for new assays and applications is significant, with a continuous demand for innovative solutions. The timeline for this development is ongoing, with potential for new product launches within the next 1-2 years. SomaLogic's competitive advantage lies in its expertise in SOMAmer technology and its ability to rapidly develop and validate new assays.
Opportunities
- Expansion into new therapeutic areas such as oncology and immunology.
- Strategic partnerships with major pharmaceutical companies.
- Increased adoption of SomaScan in clinical diagnostics.
- Geographic expansion into international markets.
Threats
- Competition from alternative protein analysis technologies.
- Regulatory hurdles in diagnostic applications.
- Patent expiration risks for SOMAmer technology.
- Economic downturn may impact research and development spending.
Competitive Advantages
- Proprietary SOMAmer Technology: SomaLogic's slow off-rate modified aptamers (SOMAmers) provide a unique competitive advantage in protein binding and analysis.
- Multiplexing Capabilities: The SomaScan platform enables multiplex protein detection and quantification, offering comprehensive protein profiling.
- Extensive Protein Coverage: SomaLogic's platform covers a broad range of proteins, providing valuable insights into biological processes and disease mechanisms.
About SLGCW
SomaLogic, Inc., founded in 1999 and headquartered in Boulder, Colorado, is a protein biomarker discovery and clinical diagnostics company. The company is focused on developing and commercializing its proprietary SomaScan platform, which leverages slow off-rate modified aptamers (SOMAmers). These SOMAmers are modified nucleic acid-based protein binding reagents designed to specifically bind to target proteins. SomaLogic's core offering is the SomaScan service, which enables multiplex protein detection and quantification of protein levels in complex biological samples, allowing researchers to analyze various types of biological samples for protein biomarker signatures. These signatures are then utilized in drug discovery and development, diagnostic applications, and gaining new insights into human biology. SomaLogic's technology supports research in areas such as cardiovascular and metabolic disease, nonalcoholic steatohepatitis, and wellness. The company serves a diverse customer base, including pharmaceutical and biotechnology companies, as well as academic research institutions, facilitating drug development, analysis of clinical trials, and the assessment of protein-protein and protein-gene networks. SomaLogic also provides SomaSignal research use only and laboratory-developed tests.
What They Do
- Develop slow off-rate modified aptamers (SOMAmers) for protein binding.
- Offer SomaScan services for multiplex protein detection and quantification.
- Provide protein biomarker discovery services for drug development.
- Support analysis of clinical trials through protein profiling.
- Facilitate new human biology insights by assessing protein networks.
- Offer SomaSignal research use only and laboratory-developed tests.
- Serve pharmaceutical and biotechnology companies, and academic research institutions.
Business Model
- SomaLogic generates revenue through its SomaScan service, providing multiplex protein analysis to research and clinical customers.
- The company also generates revenue through SomaSignal research use only and laboratory-developed tests.
- SomaLogic partners with pharmaceutical and biotechnology companies to integrate SomaScan into their drug development programs.
Industry Context
SomaLogic, Inc. operates within the healthcare information services industry, a sector experiencing growth driven by the increasing demand for personalized medicine and advanced diagnostics. The market for protein biomarker discovery is expanding, fueled by advancements in proteomics and the need for more effective drug development tools. The competitive landscape includes companies offering alternative protein analysis technologies and diagnostic platforms. SomaLogic's SomaScan platform differentiates itself through its multiplexing capabilities and the use of SOMAmers. The industry is characterized by innovation, regulatory scrutiny, and the need for robust validation of diagnostic tests.
Key Customers
- Pharmaceutical companies use SomaLogic's services for drug discovery and development.
- Biotechnology companies utilize SomaLogic's technology for protein biomarker identification.
- Academic research institutions employ SomaLogic's platform for basic research and translational studies.
Financials
Chart & Info
SomaLogic, Inc. (SLGCW) stock price: Price data unavailable
Latest News
No recent news available for SLGCW.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SLGCW.
Price Targets
Wall Street price target analysis for SLGCW.
MoonshotScore
What does this score mean?
The MoonshotScore rates SLGCW's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Stephen A. Williams BS, MB,
CEO
Stephen A. Williams brings a wealth of experience to his role as CEO of SomaLogic, Inc. His background includes a Bachelor of Science (BS) degree and a Master of Business Administration (MBA). Prior to joining SomaLogic, Williams held leadership positions in various healthcare and biotechnology companies, where he focused on strategic planning, business development, and commercialization. His expertise spans across diagnostics, therapeutics, and life sciences, making him well-suited to lead SomaLogic in its mission to advance protein biomarker discovery and clinical diagnostics.
Track Record: Under Stephen A. Williams' leadership, SomaLogic has focused on expanding the applications of its SomaScan platform and forging strategic partnerships. Key achievements include increasing the adoption of SomaScan in drug development programs and clinical trials. His strategic decisions have positioned the company for growth in the competitive healthcare information services industry. Williams continues to drive innovation and commercialization efforts to enhance SomaLogic's market position.
Common Questions About SLGCW
What does SomaLogic, Inc. do?
SomaLogic, Inc. is a protein biomarker discovery and clinical diagnostics company that develops and commercializes its proprietary SomaScan platform. The SomaScan platform leverages slow off-rate modified aptamers (SOMAmers) to enable multiplex protein detection and quantification in complex biological samples. This technology allows researchers and clinicians to analyze protein biomarker signatures for drug discovery, clinical trials, and diagnostic applications. SomaLogic serves pharmaceutical and biotechnology companies, as well as academic research institutions, providing valuable insights into human biology and disease mechanisms.
What do analysts say about SLGCW stock?
Analyst consensus for SLGCW stock is pending, as AI analysis is not yet available. Key valuation metrics to consider include the company's market capitalization, gross margin, and profit margin. Growth considerations include the potential for expanding the applications of SomaScan in drug development and clinical diagnostics, as well as the risks associated with competition and regulatory hurdles. Investors should conduct their own due diligence and consider their individual risk tolerance before making any investment decisions.
What are the main risks for SLGCW?
The main risks for SLGCW include competition from alternative protein analysis technologies, regulatory hurdles in diagnostic applications, and patent expiration risks for SOMAmer technology. The company's negative profit margin also poses a risk, as it indicates challenges in achieving overall profitability. Additionally, dependence on key personnel and potential for loss of expertise could impact the company's operations. Investors should carefully consider these risks before investing in SLGCW.
What are the key factors to evaluate for SLGCW?
SomaLogic, Inc. (SLGCW) currently holds an AI score of 55/100, indicating moderate score. Key strength: Proprietary SOMAmer technology provides a competitive advantage.. Primary risk to monitor: Potential: Competition from alternative protein analysis technologies and diagnostic platforms.. This is not financial advice.
How frequently does SLGCW data refresh on this page?
SLGCW prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven SLGCW's recent stock price performance?
Recent price movement in SomaLogic, Inc. (SLGCW) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary SOMAmer technology provides a competitive advantage.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider SLGCW overvalued or undervalued right now?
Determining whether SomaLogic, Inc. (SLGCW) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying SLGCW?
Before investing in SomaLogic, Inc. (SLGCW), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- AI analysis is pending and may provide additional insights.
- This dossier is for informational purposes only and does not constitute investment advice.